BLA 761140 · Amgen INC
Riabni
Rituximab-Arrx · Injection · CD20-directed Cytolytic Antibody
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Dec 17, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
2,564
526 Phase 3, 340 recruiting
FAERS reports
384
63 serious, 14 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY Infusion-Related Reactions Administration of rituximab products can result in serious, including fatal, infusion-related reactions. Deaths within 24 hours of rituximab infusion have occurred. Approximately 80% of fatal infusion-related reactions occurred in association with the first infusion. Monitor patients closely. Discontinue RIABNI infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion-related reactions [see Warnings and Precautions (5.1) , Adverse Reactions (6.1) ] . Severe Mucocutaneous Reactions Severe, including fatal, mucocutaneous reactions can occur in patients receiving rituximab products [see Warnings and Precautions (5.2) ] . Hepatitis B Virus (HBV) Reactivation HBV reactivation can occur...
What it is approved for
From the label in effect Oct 1, 2026.
RIABNI is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to-severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). 1.1 Non-Hodgkin's Lymphoma (NHL) RIABNI is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line...
Mechanism: Rituximab-arrx is a monoclonal antibody. Rituximab products target the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab products mediate B-cell lysis. Possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC). B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- RIABNI · RITUXIMAB-ARRX 100MG/10ML(10MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rituximab" as an intervention, any sponsor and status, largest first.
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic DiseasesPivotal-lookingActive, not recruiting
University of Sao Paulo General HospitalAcademic, hospital or other
NCT05879419 · 2,005 participants (planned) · Start May 23, 2023 · Primary completion Dec 1, 2025
Drug: Recombinant Herpes Zoster Vaccine (RZV) · For: Rheumatoid Arthritis; Spondylitis, Ankylosing; Spondyloarthritis and 8 more
Sites: São Paulo, Brazil
- Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaPivotal-lookingCompleted
German High-Grade Non-Hodgkin's Lymphoma Study GroupAcademic, hospital or other
NCT00052936 · 1,506 participants · Start Jan 2001 · Primary completion Aug 5, 2010
Drug: filgrastim; rituximab and 5 more · For: Lymphoma
Sites: Aachen, Germany; Amberg, Germany; Ansbach, Germany · 174 sites in all
- HD18 for Advanced Stages in Hodgkins LymphomaPivotal-lookingCompleted
University of CologneAcademic, hospital or other
NCT00515554 · 1,500 participants · Start May 2008 · Primary completion Jul 2019
Drug: Rituximab; BEACOPP escalated · For: Hodgkins Lymphoma
Sites: Cologne, Germany
- A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)Pivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01287741 · 1,418 participants · Start Jul 26, 2011 · Primary completion Apr 29, 2016
Drug: Rituximab; Obinutuzumab and 4 more · For: Diffuse Large B-Cell Lymphoma
Sites: Birmingham, Alabama; Chandler, Arizona; Tucson, Arizona · 235 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01332968 · 1,401 participants · Start Jul 6, 2011 · Primary completion Feb 1, 2016
Drug: Obinutuzumab; Cyclophosphamide and 5 more · For: Non-Hodgkin's Lymphoma
Sites: Springdale, Arkansas; Irvine, California; Post Falls, Idaho · 183 sites in all
- Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin LymphomasPivotal-lookingStatus unknown
Jurgen BarthAcademic, hospital or other
NCT00877214 · 1,272 participants · Start Apr 1, 2009 · Primary completion Dec 2024
Drug: Rituximab; Rituximab / observation · For: Follicular Lymphomas; Immunocytomas; Marginal Zone Lymphomas and 3 more
Sites: Giessen, Germany
- Primary Rituximab and MaintenancePivotal-lookingCompleted
Lymphoma Study AssociationAcademic, hospital or other
NCT00140582 · 1,217 participants · Start Dec 2004 · Primary completion May 2007
Drug: Rituximab · For: Follicular Lymphoma
Sites: Buenos Aires, Argentina; Melbourne, Australia; Ghent, Belgium · 24 sites in all
- A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Pivotal-lookingNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07911553 · 1,200 participants (planned) · Start Dec 22, 2026 · Primary completion Sep 2, 2030
Drug: Surovatamig; Rituximab and 5 more · For: Large B-cell Lymphoma
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product storage error165
- circumstance or information capable of leading to medication error116
- off label use64
- intercepted product administration error51
- fatigue19
- infusion related reaction18
- accidental exposure to product17
- drug ineffective16
- dyspnoea16
- intercepted product preparation error16
- malaise15
- pruritus15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 8 |
| 2022 | 49 |
| 2023 | 121 |
| 2024 | 143 |
| 2025 | 39 |
| 2026 | 22 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Riabni (Rituximab-Arrx)
2024 spending
$6.8M
Beneficiaries
309
966 claims
Per beneficiary
$22,003
$67.74 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $68,598 |
| 2022 | $1,062,069 |
| 2023 | $2,862,505 |
| 2024 | $6,798,902 |
Part B: Riabni (Rituximab-Arrx) · HCPCS Q5123
2024 spending
$92.4M
Beneficiaries
8,580
31,075 claims
Per beneficiary
$10,775
2024 ASP limit $40.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $11,960,083 |
| 2022 | $28,084,383 |
| 2023 | $42,878,562 |
| 2024 | $92,447,260 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Wang M, Salek D, Belada D, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Multicenter Study
- Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF, Kipps TJ, Eichhorst B, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, et al. · J Clin Oncol 2019 · Clinical Trial, Phase III, Multicenter Study
- Rituximab for Relapsing Nephrotic Syndrome in Adults: A Randomized Clinical Trial.
Isaka Y, Sakaguchi Y, Shinzawa M, et al. · JAMA 2025 · Randomized Controlled Trial, Multicenter Study
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Stone JH, Merkel PA, Spiera R, et al. · N Engl J Med 2010 · Multicenter Study, Randomized Controlled Trial
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.